Zimmer Biomet Holdings Inc. (NYSE:ZBH) has earned an average rating of “Buy” from the twenty-six research firms that are currently covering the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $131.74.

A number of analysts have commented on the company. Jefferies Group restated a “buy” rating and issued a $150.00 price target on shares of Zimmer Biomet Holdings in a research report on Monday, August 8th. BMO Capital Markets restated a “buy” rating and issued a $146.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 29th. JPMorgan Chase & Co. upped their price target on Zimmer Biomet Holdings from $134.00 to $148.00 and gave the stock an “overweight” rating in a research report on Friday, July 29th. JMP Securities upped their price target on Zimmer Biomet Holdings from $131.00 to $145.00 and gave the stock a “market outperform” rating in a research report on Friday, July 29th. Finally, SunTrust Banks Inc. assumed coverage on Zimmer Biomet Holdings in a research report on Thursday, August 11th. They issued a “buy” rating and a $155.00 price target for the company.

Shares of Zimmer Biomet Holdings (NYSE:ZBH) traded up 1.68% during trading on Friday, hitting $102.70. The company had a trading volume of 347,249 shares. Zimmer Biomet Holdings has a 52 week low of $88.27 and a 52 week high of $133.21. The stock has a market capitalization of $20.57 billion, a P/E ratio of 57.50 and a beta of 1.28. The firm’s 50 day moving average is $114.43 and its 200-day moving average is $121.78.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings data on Monday, October 31st. The company reported $1.79 EPS for the quarter, meeting analysts’ consensus estimates of $1.79. The company earned $1.83 billion during the quarter, compared to analysts’ expectations of $950.20 million. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. Zimmer Biomet Holdings’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.64 earnings per share. Equities research analysts anticipate that Zimmer Biomet Holdings will post $7.92 EPS for the current fiscal year.

In other news, insider Daniel E. Williamson sold 2,716 shares of the stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $129.96, for a total value of $352,971.36. Following the sale, the insider now directly owns 2,000 shares in the company, valued at $259,920. The sale was disclosed in a document filed with the SEC, which is available at this link. 1.22% of the stock is owned by insiders.

Several large investors have recently modified their holdings of ZBH. D.A. Davidson & CO. increased its stake in shares of Zimmer Biomet Holdings by 41.1% in the third quarter. D.A. Davidson & CO. now owns 15,035 shares of the company’s stock valued at $1,953,000 after buying an additional 4,380 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Zimmer Biomet Holdings by 22.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 436,580 shares of the company’s stock valued at $56,764,000 after buying an additional 80,880 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new position in Zimmer Biomet Holdings during the third quarter valued at approximately $1,127,000. LPL Financial LLC increased its position in Zimmer Biomet Holdings by 8.4% in the third quarter. LPL Financial LLC now owns 7,980 shares of the company’s stock valued at $1,031,000 after buying an additional 616 shares during the last quarter. Finally, Credit Suisse AG increased its position in Zimmer Biomet Holdings by 42.1% in the third quarter. Credit Suisse AG now owns 381,828 shares of the company’s stock valued at $49,645,000 after buying an additional 113,193 shares during the last quarter. Hedge funds and other institutional investors own 88.87% of the company’s stock.

WARNING: This piece of content was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/25/zimmer-biomet-holdings-inc-zbh-receives-average-rating-of-buy-from-analysts.html.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.